BioCentury | May 5, 2003
Company News

m-phasys management update

m-phasys GmbH , Tubingen, Germany Business: Proteomics Departed: Marc Lohrmann as managing director and CBO; he will become a director WIR Staff...
BioCentury | Jun 3, 2002
Company News

Cytomyx plc, m-phasys deal

...CYX will supply to m-phasys more than 250 full-length cell membrane receptor genes. m-phasys will use...
...produce the membrane proteins in a purified and functional state. Cytomyx plc (LSE:CYX), Cambridge, U.K. m-phasys GmbH...
BioCentury | Jun 3, 2002
Finance

Ebb & Flow

...news that it will supply more than 250 full-length genes for cell membrane receptors to m-phasys...
BioCentury | May 28, 2002
Company News

Cytomyx, m-phasys membrane receptor deal

...will supply more than 250 full-length genes for cell membrane receptors to m-phasys (Tubingen, Germany). m-phasys...
BioCentury | Apr 15, 2002
Company News

Key Drug Prototyping BV, m-phasys deal

...companies will jointly commercialize any resulting discoveries. Key Drug Prototyping BV , Leiden, the Netherlands m-phasys GmbH...
BioCentury | Apr 11, 2002
Company News

m-phasys, Key in GPCR deal

m-phasys (Tubingen, Germany) will use its M-Fold refolding technology to produce functional, purified G protein-coupled receptors (GPCRs) for Key Drug Prototyping (Leiden, the Netherlands). Key will crystallize the GPCRs and determine their structures using X-ray...
BioCentury | Dec 17, 2001
Emerging Company Profile

Corporate Profile

m-phasys GmbH Tubingen, Germany Technology: M-Fold protein refolding technology Disease focus: NA Clinical status: NA Founded: 1999 by Hans Kiefer, Wolfgang Arndt and Marc Lohrmann Corporate partners: Bayer, Glaxo-SmithKline, Cosmix, Graffinity, Medarex, Flyion University collaborators:...
BioCentury | Dec 17, 2001
Emerging Company Profile

m-phasys: Crystal clear GPCRs

...attractive classes of membrane bound proteins such as G protein-coupled receptors (GPCRs) and ion channels. m-phasys GmbH...
...the goal is to see if certain of GSK's technology works with m-phasys' refolded proteins. m-phasys...
...protein, Lohrmann said. m-phasys and the partner then would share in the crystallization work, and m-phasys...
BioCentury | Dec 17, 2001
Emerging Company Profile

Corporate Profile

m-phasys GmbH Tubingen, Germany Technology: M-Fold protein refolding technology Disease focus: NA Clinical status: NA Founded: 1999 by Hans Kiefer, Wolfgang Arndt and Marc Lohrmann Corporate partners: Bayer, Glaxo-SmithKline, Cosmix, Graffinity, Medarex, Flyion University collaborators:...
BioCentury | Nov 19, 2001
Company News

Medarex, m-phasys deal

...will develop and market human antibodies against G protein-coupled receptors (GPCRs). The companies will use m-phasys'...
...The companies will share costs and commercialization rights to products. Medarex Inc. (MEDX), Princeton, N.J. m-phasys GmbH...
Items per page:
1 - 10 of 21
BioCentury | May 5, 2003
Company News

m-phasys management update

m-phasys GmbH , Tubingen, Germany Business: Proteomics Departed: Marc Lohrmann as managing director and CBO; he will become a director WIR Staff...
BioCentury | Jun 3, 2002
Company News

Cytomyx plc, m-phasys deal

...CYX will supply to m-phasys more than 250 full-length cell membrane receptor genes. m-phasys will use...
...produce the membrane proteins in a purified and functional state. Cytomyx plc (LSE:CYX), Cambridge, U.K. m-phasys GmbH...
BioCentury | Jun 3, 2002
Finance

Ebb & Flow

...news that it will supply more than 250 full-length genes for cell membrane receptors to m-phasys...
BioCentury | May 28, 2002
Company News

Cytomyx, m-phasys membrane receptor deal

...will supply more than 250 full-length genes for cell membrane receptors to m-phasys (Tubingen, Germany). m-phasys...
BioCentury | Apr 15, 2002
Company News

Key Drug Prototyping BV, m-phasys deal

...companies will jointly commercialize any resulting discoveries. Key Drug Prototyping BV , Leiden, the Netherlands m-phasys GmbH...
BioCentury | Apr 11, 2002
Company News

m-phasys, Key in GPCR deal

m-phasys (Tubingen, Germany) will use its M-Fold refolding technology to produce functional, purified G protein-coupled receptors (GPCRs) for Key Drug Prototyping (Leiden, the Netherlands). Key will crystallize the GPCRs and determine their structures using X-ray...
BioCentury | Dec 17, 2001
Emerging Company Profile

Corporate Profile

m-phasys GmbH Tubingen, Germany Technology: M-Fold protein refolding technology Disease focus: NA Clinical status: NA Founded: 1999 by Hans Kiefer, Wolfgang Arndt and Marc Lohrmann Corporate partners: Bayer, Glaxo-SmithKline, Cosmix, Graffinity, Medarex, Flyion University collaborators:...
BioCentury | Dec 17, 2001
Emerging Company Profile

m-phasys: Crystal clear GPCRs

...attractive classes of membrane bound proteins such as G protein-coupled receptors (GPCRs) and ion channels. m-phasys GmbH...
...the goal is to see if certain of GSK's technology works with m-phasys' refolded proteins. m-phasys...
...protein, Lohrmann said. m-phasys and the partner then would share in the crystallization work, and m-phasys...
BioCentury | Dec 17, 2001
Emerging Company Profile

Corporate Profile

m-phasys GmbH Tubingen, Germany Technology: M-Fold protein refolding technology Disease focus: NA Clinical status: NA Founded: 1999 by Hans Kiefer, Wolfgang Arndt and Marc Lohrmann Corporate partners: Bayer, Glaxo-SmithKline, Cosmix, Graffinity, Medarex, Flyion University collaborators:...
BioCentury | Nov 19, 2001
Company News

Medarex, m-phasys deal

...will develop and market human antibodies against G protein-coupled receptors (GPCRs). The companies will use m-phasys'...
...The companies will share costs and commercialization rights to products. Medarex Inc. (MEDX), Princeton, N.J. m-phasys GmbH...
Items per page:
1 - 10 of 21